UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~November~~January 1912, ~~2008~~2009

SUTURA, INC.

(Exact name of registrant as specified in its charter)


Delaware (State or other jurisdiction of incorporation)		000-25548 (Commission File Number)		84-1010269 (IRS Employer Identification No.)


17080 Newhope Street, Fountain Valley, California (Address of principal executive offices)		92708 (Zip Code)

Registrant’s telephone number, including area code: (714) 437-9801

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

This Form 8-K, as well as other reports filed by the Registrant from time to time with the Securities and Exchange Commission (collectively the “Filings”), contain forward looking statements and information that are based upon beliefs of, and information currently available to, the Registrant’s management as well as estimates and assumptions made by the Registrant’s management. When used in the Filings the words “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan” or the negative of these terms and similar expressions as they relate to the Registrant or the Registrant’s management identify forward looking statements. Such statements reflect the current view of the Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to the Registrant’s industry, operations and results of operations and any businesses that may be acquired by the Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Section 45 — ~~Matters~~Corporate ~~Related~~Governance ~~to Accountants~~ and ~~Financial Statements~~Management

Item 4 5.02. ~~Non-Reliance~~Departure onof ~~Previously~~Directors ~~Issued~~or ~~Financial~~Principal ~~Statements~~Officers; orElection aof ~~Related~~Directors; ~~Audit~~Appointment ~~Report or~~of ~~Completed~~Principal ~~Interim Review.~~ Officers

On To ~~July 1, 2007, Registrant and~~ the ~~Whitebox~~extent ~~affiliated~~required ~~parties~~by ~~amended the Whitebox I, Whitebox II and Whitebox III convertible notes~~Item 5.02 ~~Included in the amendments was an extension~~ of ~~the maturity~~Form ~~dates~~8-K, ~~of each of~~ the ~~notes~~information ~~until~~contained ~~July 1,~~in ~~2009, payment of a 3% consent fee, and a~~or ~~reduction~~incorporated toby ~~the~~reference ~~conversion~~into ~~rate to $~~Item 8.0801 ~~per share. At the time~~ of ~~the~~this ~~amendment~~Current ofReport ~~the~~is ~~notes, Registrant~~hereby ~~determined~~incorporated ~~that~~by ~~there was no intrinsic value resulting from the reduction of the~~reference ~~conversion~~into ~~price~~this ~~to $~~Item 5.~~08 and did not treat the amendments as new loans as the notes were amended and new notes were not issued~~02.

However, in response to a comment letter received from the United States Securities and Exchange Commission (“SEC”) and discussions with the SEC Staff, Registrant has determined that the July 1st, 2007 extension and changes in the terms of the Whitebox Notes I, II and III should have been accounted for as new notes rather than extensions of existing notes per FASB EITF 96-17. Accordingly, certain balance sheet entries, loss figures and expense figures in the Registrant’s Quarterly Reports for the periods ended SeptemberSection ~~30,~~8 ~~2007,~~— ~~March 31,~~Financial ~~2008~~Statements and ~~June 30, 2008 should~~Exhibits not be relied upon as indicated below. Further, the accumulated deficit amounts contained in Registrant’s Annual Report for the year-ended December 31, 2007 should not be relied upon as indicated below.

~~The~~Item ~~difference is the immediate amortization of the $634,996 beneficial conversion feature on our books as of July 1st, 2007 rather than amortization per our original schedule~~8. For purposes of Registrant’s Quarterly Report for the period ending September 30, 2008, and for periods thereafter, the September 30, 2007 outstanding notes payables will be increased by $634,996 and third quarter 2007 interest expenses also by $634,99601. ~~The~~Other effect of these corrections on the third quarter of 2007 was an increase in interest expenses from $998,992 to $1,633,988. The net loss from operations increased from $2,936,132 to $3,571,128. For the year to date end of September 2007, interest expenses increased from $3,182,660 to $ $3,817,656 and the net loss increased from $8,674,288 till $9,309,284. In the balance sheet for Registrant’s Annual Report for the year ended December 31, 2007 accumulated deficit was increased by $472,467 from $57,661,739 to $58,134,208. Events

~~Authorized~~ Effective ~~officers~~January 12, ~~discussed~~2009, ~~with~~Mr. Anthony ~~the~~Nobles resigned from Registrant’s ~~independent~~Board ~~accountant~~of Directors (the ~~matters~~“Board”) ~~disclosed~~and infrom his positions as President and Chief ~~this~~Science ~~Current~~Officer ~~Report~~of Registrant, and such resignations were accepted by the Board pursuant at a meeting held on that same date. Mr. Nobles remains an employee of Registrant in accordance with the remainder of the terms of his employment agreement.

Mr. Nobles is the President and Chief Executive Officer and a director of Nobles Medical Technologies, Inc, a Delaware corporation (“Nobles Medical”). On December 12, 2008, Registrant entered into an Asset Purchase Agreement providing for the sale of all of Registrant’s non-cash assets and $3.0 million of its cash and cash equivalents to Nobles Medical in exchange for a cash payment of $6.75 million. Since November 3, 2008 and pursuant to a letter agreement between the parties, Nobles Medical and its designated representatives have been managing and been in charge of the operations and day-to-day business of Registrant, subject to oversight by Registrant’s Board of Directors as is required for the Board to exercise its fiduciary duties.

Section 9 — Financial Statements and Exhibits


Item 9.01		Financial Statements and Exhibits

(a) Financial statements of business acquired. Not applicable (b) Pro forma financial information. Not applicable (c) Shell Company Transactions Not Applicable (d) Exhibits. None

Not applicable

(b) Pro forma financial information.

Not applicable

Not Applicable

(d) Exhibits.

Not Applicable

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SUTURA, INC. (Registrant)
Date: November 19, 2008	/s/ Richard Bjorkman
Date: January 16, 2009	/s/ Brian Abraham
	Richard Bjorkman
	Brian Abraham
	Chief Financial Officer
	Chief Executive Officer

Filing Compare · Sutura, Inc.